Find an expert
Our panel of editors are available for interview
Dr James Mountford
Editor-in-Chief of BMJ Leader
Dr James Mountford is Director of Quality at Royal Free London NHS Foundation Trust. He worked initially as an NHS doctor, then in consulting. From 2005-2007, he was a Commonwealth Fund Health Foundation Harkness Fellow based in Massachusetts General Hospital, and at the Institute for Healthcare Improvement (IHI), both in Boston, USA. Before moving to the Royal Free, he was Director of Quality at UCL Partners, an academic health sciences partnership serving a population of 3 million in and around London. He sits on the board of AQuA, the improvement partnership based in north-west England. In March 2020 he was seconded to work as the Chief of Quality and Learning at the NHS Nightingale Hospital London, opened in response to the COVID-19 pandemic.
Dr James Cave
Editor-in-Chief of the Drugs and Therapeutics Bulletin
Dr James Cave has been a GP for over 25 years. He currently works for Red Whale, providing courses for GP’s that take the latest research and demonstrate how it might be used in practice. James was awarded an OBE for services to medicine in 2009.
Karen L Furie, MD
Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry
Karen Furie, MD, MPH is Neurologist-in-Chief, Rhode Island Hospital, the Miriam Hospital and Bradley Hospital Samuel I Kennison, MD and Bertha S Kennison Professor of Clinical Neuroscience Chair of Neurology, the Warren Alpert Medical School of Brown University. Clinical and translational stroke research has been a major focus of Karen’s career, and she has enjoyed success in developing collaborative multispecialty initiatives.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
